Current and historical daily PE Ratio for SBHMY (
Sino Biopharmaceutical Ltd
) from 2014 to May 25 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Sino Biopharmaceutical stock (SBHMY) PE ratio as of May 25 2024 is 20.72.
More Details
Sino Biopharmaceutical Ltd (SBHMY) PE Ratio (TTM) Chart
Sino Biopharmaceutical Ltd (SBHMY) PE Ratio (TTM) Historical Data
View and export this data going back to 2014. Start your Free Trial
Total 1235
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Sino Biopharmaceutical PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-25 | 20.4 | 2024-03-22 | 23.3 |
| 2024-05-24 | 20.4 | 2024-03-21 | 23.3 |
| 2024-05-23 | 20.4 | 2024-03-20 | 23.3 |
| 2024-05-22 | 20.4 | 2024-03-19 | 23.3 |
| 2024-05-21 | 20.4 | 2024-03-18 | 23.3 |
| 2024-05-20 | 20.4 | 2024-03-15 | 21.1 |
| 2024-05-17 | 20.4 | 2024-03-14 | 21.1 |
| 2024-05-16 | 20.4 | 2024-03-13 | 21.1 |
| 2024-05-15 | 20.4 | 2024-03-12 | 21.1 |
| 2024-05-14 | 20.4 | 2024-03-11 | 21.1 |
| 2024-05-13 | 20.4 | 2024-03-08 | 21.1 |
| 2024-05-10 | 20.4 | 2024-03-07 | 21.1 |
| 2024-05-09 | 20.4 | 2024-03-06 | 21.1 |
| 2024-05-08 | 20.4 | 2024-03-05 | 21.1 |
| 2024-05-07 | 20.4 | 2024-03-04 | 22.6 |
| 2024-05-06 | 20.4 | 2024-03-01 | 22.6 |
| 2024-05-03 | 20.4 | 2024-02-29 | 22.6 |
| 2024-05-02 | 20.4 | 2024-02-28 | 22.6 |
| 2024-05-01 | 20.4 | 2024-02-27 | 22.6 |
| 2024-04-30 | 20.4 | 2024-02-26 | 21.5 |
| 2024-04-29 | 20.4 | 2024-02-23 | 21.5 |
| 2024-04-26 | 20.4 | 2024-02-22 | 21.5 |
| 2024-04-25 | 20.4 | 2024-02-21 | 21.5 |
| 2024-04-24 | 20.4 | 2024-02-20 | 21.5 |
| 2024-04-23 | 20.4 | 2024-02-16 | 21.5 |
| 2024-04-22 | 20.4 | 2024-02-15 | 21.5 |
| 2024-04-19 | 20.4 | 2024-02-14 | 21.5 |
| 2024-04-18 | 20.4 | 2024-02-13 | 21.5 |
| 2024-04-17 | 20.4 | 2024-02-12 | 21.6 |
| 2024-04-16 | 20.4 | 2024-02-09 | 20.8 |
| 2024-04-15 | 20.4 | 2024-02-08 | 26.7 |
| 2024-04-12 | 20.4 | 2024-02-07 | 26.7 |
| 2024-04-11 | 20.4 | 2024-02-06 | 26.7 |
| 2024-04-10 | 20.4 | 2024-02-05 | 26.7 |
| 2024-04-09 | 20.4 | 2024-02-02 | 26.7 |
| 2024-04-08 | 20.4 | 2024-02-01 | 26.7 |
| 2024-04-05 | 21.1 | 2024-01-31 | 26.7 |
| 2024-04-04 | 21.1 | 2024-01-30 | 26.7 |
| 2024-04-03 | 21.0 | 2024-01-29 | 26.7 |
| 2024-04-02 | 23.3 | 2024-01-26 | 26.7 |
| 2024-04-01 | 23.3 | 2024-01-25 | 26.7 |
| 2024-03-28 | 23.3 | 2024-01-24 | 26.7 |
| 2024-03-27 | 23.3 | 2024-01-23 | 26.7 |
| 2024-03-26 | 23.3 | 2024-01-22 | 26.7 |
| 2024-03-25 | 23.3 | 2024-01-19 | 26.7 |
Sino Biopharmaceutical Ltd (SBHMY) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Sino Biopharmaceutical Ltd
NAICS : 325412
ISIN : US82937X1037
Share Class Description:
SBHMY: ADRCompare
Compare
Traded in other countries / regions
01177.Hong KongSMZ1.GermanySBHMY.USA IPO Date
2014-04-22Description
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers